Ovid Therapeutics
OVID
80 hedge funds and large institutions have $131M invested in Ovid Therapeutics in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 28 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.9% less ownership
Funds ownership: 55.14% → 49.24% (-5.9%)
9% less funds holding
Funds holding: 88 → 80 (-8)
10% less capital invested
Capital invested by funds: $146M → $131M (-$15.1M)
25% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 28
37% less call options, than puts
Call options by funds: $1.78M | Put options by funds: $2.83M
40% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Globeflex Capital
San Diego,
California
|
+$3.98M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.46M |
| 3 |
Millennium Management
New York
|
+$3.02M |
| 4 |
Two Sigma Investments
New York
|
+$1.14M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$843K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$9.86M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.13M |
| 3 |
Goldman Sachs
New York
|
-$2.52M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.91M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.58M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Invesco
Atlanta,
Georgia
| – | -$45K | -11,254 | Closed |
|
102
Legal & General Group
London,
United Kingdom
| – | -$21K | -5,199 | Closed |
|
|
AIP
103
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$15K | -3,782 | Closed |
|
104
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$5K | -1,333 | Closed |
|
|
HR
105
Howe & Rusling
Rochester,
New York
| – | -$1K | -180 | Closed |
|
|
EI
106
Ellevest Inc
New York
| – | +$209 | +53 | New |
|
OVID Hedge Fund Activity: Q2 2021 in Review
80 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2021, worth a combined $131M — down 10% from $146M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of OVID and 21 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 18 added.
The largest buyer was Globeflex Capital, opening a new position worth an estimated $3.98M. The largest seller was BlackRock, cutting an estimated $9.86M.
- 80 institutional investors held Ovid Therapeutics (OVID) as of Q2 2021, down from 88 in Q1 2021.
- Funds reported $131M of Ovid Therapeutics stock for Q2 2021, down 10% quarter-over-quarter.
- 21 funds opened new Ovid Therapeutics positions in Q2 2021 and 28 closed out, a net change of -7 holders.
- The largest Ovid Therapeutics buyer in Q2 2021 was Globeflex Capital, an estimated $3.98M added.
- The largest Ovid Therapeutics seller in Q2 2021 was BlackRock, an estimated $9.86M sold.
Based on aggregated 13F filings for Q2 2021.